Skip to main content

Table 7 Cell cycle alteration after treatment with bortezomib (Bor) and temozolomide (TMZ)

From: Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis

Cell lineGroupPercentage of cells in different cell cycle phases (%)
G1SG2
U25120 nmol/L Bor52.5 ± 3.9935.98 ± 2.9611.52 ± 1.66
200 μmol/L TMZ54.45 ± 4.8832.77 ± 3.2512.78 ± 1.42
Bor + TMZ78.31 ± 5.5413.83 ± 1.587.86 ± 1.26
U8720 nmol/L Bor45.67 ± 2.9930.73 ± 2.5323.63 ± 1.88
200 μmol/L TMZ66.44 ± 4.3326.19 ± 2.207.37 ± 1.94
Bor + TMZ81.40 ± 6.5112.22 ± 1.546.42 ± 2.25
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us

\